Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

JMP Securities Stick to Their Buy Rating for Allogene Therapeutics Inc

Published 10/11/2021, 10:05 PM
Updated 10/11/2021, 10:05 PM


JMP Securities analyst Reni Benjamin reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) Inc on Monday, setting a price target of $27, which is approximately 105.64% above the present share price of $13.13.

Benjamin expects Allogene Therapeutics Inc to post earnings per share (EPS) of -$0.53 for the fourth quarter of 2021.

The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Allogene Therapeutics, with an average price target of $32.92.
The analysts price targets range from a high of $45 to a low of $18.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $44 thousand and a net profit of -$71.03 million. The company's market cap is $1.87 billion.

According to TipRanks.com, JMP Securities analyst Reni Benjamin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 35.82% success rate.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.